title: Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial.
abstract: BACKGROUND
  To assess the efficacy of an abbreviated Stanford V regimen in patients with early-stage Hodgkin lymphoma (HL). PATIENTS AND METHODS PATIENTS: with untreated nonbulky stage I-IIA supradiaphragmatic HL were eligible for the G4 study. Stanford V chemotherapy was administered for 8 weeks followed by radiation therapy (RT) 30 Gy to involved fields (IF). Freedom from progression (FFP), disease-specific survival (DSS) and overall survival (OS) were estimated.
  
  
  RESULTS
  All 87 enrolled patients completed the abbreviated regimen. At a median follow-up of 10 years, FFP, DSS and OS are 94%, 99% and 94%, respectively. Therapy was well tolerated with no treatment-related deaths.
  
  
  CONCLUSIONS
  Mature results of the abbreviated Stanford V regimen in nonbulky early-stage HL are excellent and comparable to the results from other contemporary therapies.
authors.affiliation: Departments of Medicine (Oncology), Stanford University Medical Center, 875 Blake Wilbur Drive, CC-2338, Stanford, CA 94305, USA. radvani@stanford.edu
authors.forename: R H
authors.initials: RH
authors.lastname: Advani
authors.forename: R T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: D
authors.initials: D
authors.lastname: Baer
authors.forename: J
authors.initials: J
authors.lastname: Mason
authors.forename: R
authors.initials: R
authors.lastname: Warnke
authors.forename: J
authors.initials: J
authors.lastname: Allen
authors.forename: S
authors.initials: S
authors.lastname: Daadi
authors.forename: S A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: S J
authors.initials: SJ
authors.lastname: Horning
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D011241:Prednisone